The United States and many other countries are heavily dependent on supplies of pharmaceuticals and precursor chemicals from China and India. Widespread shortages resulting from the COVID-19 outbreak remain unlikely. Legislative proposals in the United States to force companies to "reshore" supply chains will likely falter on the increase in costs and regulatory hurdles. ...